PCN139 Head to Head Economic Evaluation of Two Genomic Profiles of Recurrence Risk for Breast Cancer, Mammaprint Versus Oncotype DX, in Spain  by Crespo, C. et al.
A416  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
OMS and drugs, inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: 
sick leave, premature retirement, premature mortality) were estimated by 2010 
gross domestic product/capita/day. Costs and quality-adjusted life-years (QALYs) 
were discounted by 3% per annum. Strategies with significantly different QALYs/
patient-year (PY) were compared by CUA, remaining strategies by cost-minimization 
analysis. Results: From July 2008 to March 2013, 3063 LCLRPC patients (T1a–T2c, 
N0, M0; 67.3±7.5 years) were included from 257 urologists: AS n= 452, RT n= 378, HT 
n= 210, HT+RT n= 80, combination therapy (CT) n= 137, OP n= 1647, other therapy 
(OT) n= 18, WW n= 141. Observation period: average 1.9 years, maximum 4.6 years. 
From the societal perspective (DC+IC), AS and RT each dominated HT, i.e. there 
were savings/PY (€ 257 and € 208) and QALYs gained/PY (0.0811 and 0.0587) with AS 
and RT, respectively, versus HT. When comparing OP to HT, there were additional 
cost (DC+IC) of € 5134/PY and 0.0784 QALYs gained/PY for OP versus HT leading to 
€ 65,525 per QALY gained. ConClusions: The HAROW study provides meaningful 
results on cost utility of AS, OP, RT, and HT as LCLRPC treatment strategies under 
day-to-day conditions of care in Germany to support decision making.
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objeCtives: This study evaluated the cost-effectiveness of everolimus + exemes-
tane (EVE+EXE) versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- 
metastatic breast cancer in the UK. Whilst the effectiveness of treatment has been 
demonstrated previously, this is the first analysis to assess the cost of the intervention 
alongside those benefits. Methods: A Markov model was developed to compare 
treatment with EVE+EXE versus PBO+EXE in patients with ER+ HER2- metastatic 
breast cancer over a lifetime time horizon (UK health care perspective). Follow-up data 
on progression-free survival and overall survival were taken from the BOLERO II trial. 
Weibull functions were used to extrapolate trial data beyond the follow-up period. 
Utilities from published sources were combined with trial data to calculate quality-
adjusted life years (QALYs) associated with each treatment. Drug costs (list prices) and 
background health state costs (i.e. non-intervention costs) were applied to calculate 
incremental costs offset. Results: Over a ten year time horizon, EVE+EXE led to a 
life expectancy of 3.27 years, compared to 2.41 for PBO+EXE. EVE+EXE resulted in 1.91 
QALYs, compared to 1.31 for PBO+EXE. Therefore, the incremental gains in life years 
and QALYs were 0.85 and 0.60 respectively. Drug costs were £22,074 and £628 for the 
two arms respectively, whilst non-drug costs were £22,332 and £21,108 respectively. 
Therefore, the EVE+EXE arm had an incremental cost of £22,670. The incremental cost 
per QALY was, therefore, £37,719 over a ten-year time horizon. Probabilistic sensitivity 
analysis demonstrated that, at a threshold of £30,000 per QALY gained, EVE+EXE had 
a 27.3% likelihood of being cost-effective. At a threshold of £55,000 per QALY gained, 
the likelihood of cost-effectiveness was 77.4%. ConClusions: EVE+EXE was associ-
ated with increased health care costs, but was also estimated to lead to health gains 
in terms of both LYs and QALYs.
PCN138
Cost-EffECtivENEss of gEmCitABiNE PlUs CisPlAtiN vErsUs gEmCitABiNE 
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objeCtives: Gemcitabine plus cisplatin is a common use for chemotherapy 
patients with advanced biliary tract cancer in Japan. This study aims to assess the 
cost-effectiveness of this combination therapy compared to monotherapy for bil-
iary tract cancer in Japan. Methods: A Markov model of three states and monthly 
transmissions was constructed based on a phase II trial. Transition probabilities 
between states were derived from the trial conducted by Valle, J. et al (2010). and 
converted to appropriate parameters for input into the model. The associated cost 
components, obtained from literature published in Japan, were inpatient, outpa-
tient, and medication for biliary tract cancer as well as those for palliative care. 
We estimated cost-effectiveness per quality-adjusted life year (QALY) at a time 
horizon of thirty two months. An annual discount for cost and outcome was not 
considered. Results: The model demonstrate no statistical significance in the 
hazard ratio of 0.625, as compared to an actual ratio of 0.63 (95% confidence inter-
val: 0.51–0.77) retrieved from the clinical trial. The base case outcomes indicated 
that combination therapy would be more cost-effective than monotherapy when 
the incremental cost-effectiveness ratio (ICER) was approximately 720,000 YEN 
per QALY gained, retrospectively. A tornado diagram depicting the deterministic 
sensitivity analysis of the ICER revealed that the death rate resulting from the 
combination therapy influenced the base case, but robustness of the base case 
was identified. A probabilistic analysis resulting from 5,000 Monte Carlo simula-
tions demonstrated efficacy at willingness to pay (WTP) thresholds of 5,000,000 
YEN per QALY gained in approximately 95% of the population. ConClusions: 
In Japan, combination therapy is a cost-effective treatment option for advanced 
biliary tract cancer.
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objeCtives: Cost effectiveness analysis of MammaPrint in the diagnosis of early 
breast cancer from the Spanish NHS perspective. Methods: Markov model 
nomic evaluation. Sensitivity analyses were conducted to explore the uncertainties 
surrounding the assumptions. Results: Abiraterone plus prednisolone indicated 
higher QALYs than prednisolone alone, though it was more expensive. In the base-
case analysis, ICER for abiraterone plus prednisolone exceeded JPY 10 million (EUR 
80,000) per QALY gained. The one-way sensitivity analysis for discount rate (0 to 
4%) showed no affects on the results. ConClusions: The present study concludes 
that the ICER may be more than JPY 10 million. Further deliberate discussion on 
cost-effectiveness of abiraterone in Japan is needed to consider the Japanese price 
and clinical outcomes.
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objeCtives: To assess the cost-effectiveness of a national HPV vaccination pro-
gram that vaccinates 12 year-old girls with cervical cancer screening and the only 
current cervical cancer screening. Methods: We analyzed the effect of HPV infec-
tion reduction by HPV vaccination on reduction of CIN and cervical cancer and 
finally conducted cost-utility analysis applying QALYs to which takes into account 
life span expansion and the quality of life. With the societal perspective, patient 
time costs, caregiver costs, and transportation costs were all considered as well as 
medical costs. Markov model was used with one year cycle and life time analysis 
period. Markov states in this model were classified well, HPV infection, CIN 1, CIN 
2/3, cervical cancer (initial cancer), follow-up cervical cancer, recurrent/persistent 
cancer, follow-up recurrent/persistent cancer and death. The HPV infection was 
limited to infections caused by HPV specific types 16 and 18. Results: When HPV 
vaccination program is introduced to 12-year old cohort, it was indicated that 
cervical cancer patients with HPV vaccination program would be 2,042 patients 
and cervical cancer patients with present screening program 3,709. It results that 
cervical cancer patients would be decreased to 1,667 by HPV vaccination. From 
this, it was estimated that all the cohorts would get an additional life expectancy 
of 1,648 LYG and quality adjusted life years of 1,849 QALYs. According to cost-utility 
analysis result, additional 1849 QALYs cost KRW 59.8 billion when HPV vaccination 
program implement, and the incremental cost-utility ratio was estimated to be 
KRW 32 million per a QALY. Considering the threshold of Korean cost-effective-
ness, the vaccination program is decided not to be cost-effective. ConClusions: 
Though the HPV vaccination program for 12-year old girls was not cost-effective at 
the current condition of Korea, it is advisable to consider that cost-effectiveness 
varies sensitively.
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objeCtives: Metastatic renal cell cancer (mRCC) is becoming an important part of 
Dutch health care expenditure due to expensive pharmaceutical options for disease 
control and lack of adequate prevention methods. New targeted therapeutics, such 
as sunitinib, sorafenib and everolimus, have recently emerged with relevant benefits 
on progression-free survival (PFS) for mRCC patients. This study aims to assess 
the cost-effectiveness of the most recent of these introductions, i.e. everolimus, 
in comparison to best supportive care in second line treatment of mRCC patients 
in The Netherlands. Methods: A Markov model was designed in line with Dutch 
treatment protocols. Transitions between health states were modeled by time-
dependent probabilities extracted from published Kaplan-Meier curves for PFS and 
overall survival (OS). The cohorts were followed over 18 cycles, each cycle lasting 8 
weeks. Annual discount rates of 1.5% for health and 4% for costs were applied and 
a health-care perspective was taken. One-way and probabilistic sensitivity analyses 
(PSA) were performed to test the robustness and uncertainty around the base-case 
estimate. Results: The incremental cost-effectiveness ratio (ICER) for everolimus 
was esimated at € 92,258/QALY. Sensitivity analysis identified the hazard multi-
plier, an estimate of OS gain, as the main driver of everolimus’ cost-effectiveness. 
Through PSA a wide 95% confidence interval around the base-case ICER estimate 
was revealed (€ 49,677 - € 453,941/QALY). Additionally, at the threshold of three times 
GDP per capita (€ 95,700 in The Netherlands) everolimus had a 54% probability of 
being cost-effective. ConClusions: The base-case ICER was just below the upper 
cost-effectiveness limit recommended by WHO, indicating that everolimus might 
be a cost-effective option in the Dutch setting. However, reasonable uncertainty of 
the main finding resulted from everolimus’ unpredictable gain in OS. Efforts should 
be undertaken to perform an integral assessment of the economic attractiveness 
of all current and new therapeutics in mRCC.
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Cost-Utility ANAlysis (CUA) of diffErENt strAtEgiEs to trEAt NEwly 
diAgNosEd loCAlly CoNfiNEd low-risK ProstAtE CANCEr (lClrPC) iN 
gErmANy: rEsUlts of thE hArow stUdy
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objeCtives: The optimal treatment choice for preserving quality of life (QoL) of 
the about 64,000 men diagnosed with prostate cancer each year in Germany still 
remains unclear. The objectives therefore were to estimate cost utility under day-
to-day conditions of caring for men in Germany with newly diagnosed LCLRPC 
using hormonal therapy (HT), active surveillance (AS), radiotherapy (RT), operation 
(OP), or watchful waiting (WW) – HAROW. Methods: The long-term observational 
multi-centre HAROW study combined data collection from urologists (clinical data; 
utilized outpatient medical services, OMS) and from patients (employment status, 
QoL by EQ-5D, numerous health resource use items). Resource use was valued by 
year 2010 official prices in € . Direct costs (DC) were given by hospital treatment, 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A417
PCN142
AN ovErviEw of domEstiC CANCEr drUgs iN tUrKEy: 2008-2012
Vural E.H., Safak Yilmaz E., Vural I.M., Dogan E, Akbulat A., Gursoz H., Kerman S.
Turkish Medicines and Medical Devices Agency, Ankara, Turkey
objeCtives: Cancer is among the most common causes of death in Turkey. Cancer 
diagnosis and treatment management were substantially improved by the Ministry 
of Health. Generic market and price movements of different kinds of drug groups 
show different characteristics. In this study we aimed to demonstrate the impact 
of domestic manufacture of cancer drugs on import cancer drug sales in Turkey in 
terms of both boxes and cost sale trend analysis between 2008 and 2012. Methods: 
This study was designed as an observational, retrospective study. Domestic oncol-
ogy drugs were chosen from the base oncology drug groups. The sales data of the 
domestic oncology drugs and both original and generic import drugs which have the 
same active ingredient with the domestic drugs was obtained from the Information 
Medical Statistics (IMS) database from September 2007 to July 2012. Sales data is 
evaluated with segmented regression analysis for interrupted time series. Results: 
Oncology drug sales report showed that the market share of domestic products 
increased approximately 38% at 2012 from 0,5% at 2008. Before the cut point, there 
was a statistically significant increase in the sales level of import oncology drugs, 
but after the cut point sales trend showed a statistically significant decrease. Import 
oncology drugs’ unit price per box decreased from 196.5TL between September 2007 
and October 2008 to 172.6TL between November 2008 and July 2012. But domestic 
oncology drugs’ unit price per box was 91.8TL between November 2008 and July 
2012. ConClusions: In conclusion, domestic drug manufacturing has important 
contributions to a country’s economy including low drug prices, supplying for the 
domestic consumption, creation of employment opportunities and also as export 
potentials. Price cut in 2009 and 2011 in Turkey and “Reference Pricing System” 
should be taken into consideration for this price change evaluation in the case of 
domestic product manufacturing.
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short-tErm disABility (std) AssoCiAtEd with sKElEtAl rElAtEd 
EvENts (srEs) iN CommErCiAlly iNsUrEd PAtiENts with BoNE 
mEtAstAsEs (Bm) sECoNdAry to solid tUmors
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objeCtives: Patients with BM frequently experience SREs including pathological 
fracture, surgery or radiation to bone, or spinal cord compression .The study objec-
tive was to estimate STD (work hour loss) and associated costs in patients with SREs 
in a population with BM secondary to solid tumors. Methods: Patients with diag-
nosis of solid tumors and BM were extracted from MarketScan® Health Productivity 
and Management Database and Commercial Database in 2002-2010. Eligible patients 
were 18-64 year-old full-time employees, had STD benefit eligibility, and had ≥ 6 
months continuous pre-index enrollment (pre-period) and ≥ 1 month follow-up. For 
SRE patients, index date was the first SRE claim. For patients without SREs, index 
date was assigned per the distribution of index dates from SRE patients. Monthly 
STD hours and costs associated with STD were estimated during the first (up to) 6 
months and the first (up to) 12 months. Generalized linear models estimated the 
marginal impact of having SRE on STD hours and associated costs, controlling for 
baseline STD hours and patients’ characteristics. Results: A total of 854 patients 
with SREs and 701 patients without SREs were included, with a mean age of 52.1 
and 51.6 years, respectively. 52.2% of SRE patients reported STD during the 6-month 
follow-up, compared with 19.1% of patients without SREs. For SRE patients, the 
mean STD hours were 21.2 per month in pre-period and 61.3 during follow-up. The 
hours for patients without SREs were 8.6 and 14.4, respectively. Multivariate analysis 
indicated that SREs were associated with significantly increased STD hours (39.4 
per month) and associated costs ($613 per month) during the 6-month follow-up 
period. Results from the 12-month follow-up period were similar. ConClusions: 
SREs were associated with significantly increased STD hours and associated costs. 
Therapies that prevent or delay the development of SREs may reduce work loss and 
costs associated with it.
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objeCtives: Although cancer is one of the leading causes of mortality worldwide, 
the number of cancer survivors is constantly growing due to improved treatment. 
Growing number of cancer survivors goes in line with trends to increase retirement 
age and this together leads to increase number of cancer survivors at economi-
cally active age. The aim of this study was to analyze economic activity of cancer 
survivors in Poland. Methods: Data on disability (the number of medical certifi-
cates awarded because of incapacity for work) due to cancer and other diseases 
were retrieved from the Social Insurance Institution annual report for the year 
2009. Data included the number of medical certificates issued for the first time 
and the number of certificates reissued, their periods of validity, age of population 
and disability severity (complete or partial inability to work, inability of independ-
ent existence). Results: Cancer was the second (after cardiovascular diseases) 
cause of medical certificates issued for the first time because of incapacity to work 
and account for 22% of all certificates awarded for the first time. However, the 
number of certificates reissued was significantly lower – cancer accounted for 7% 
of all certificates reissued (cardiovascular diseases still accounted for the largest 
number of certificates reissued – 25%). The mean age of population with cancer 
was above the mean age of overall population with medical certificates awarded 
because of incapacity to work, however lower than those for cardiovascular or 
pulmonary diseases. Significant differences in disability severity structure exist. 
Significant higher percentage of cancer patients were judged as either incapable of 
independent existence (19.9%-24.9% compare to 4.4%-6.5% in overall population) or 
complete incapable to work (45.9%-71.1% compare to 23.4%-32.9% in overall popula-
assuming a 60-year-old women cohort with negative-lymph node, positive estro-
gen receptors and negative HER2 breast cancer. Costs and effects of the treatment 
by identifying recurrence risk using A!O, MammaPrint or OncotypeDX were com-
pared at 5 years, 10 years and lifetime horizons. Probability of low or high risk of 
recurrence by A!O was fixed 50/50 (ratios between 40/60 and 60/40 for sensitivity 
analysis). Risks predicted by OncotypeDX and MammaPrint were assumed to be the 
same. Cost of chemotherapy (2.825€ ), recurrence (6,357€ ) and other direct health 
care costs were derived from local data. Three health states (free of recurrence, 
recurrence, death) were defined in a given period of time. Results: A total of 31% 
patients required adjuvant chemotherapy with MammaPrint classification (36.6% 
with OncotypeDX, 56.3% with A!O). MammaPrint showed a life expectancy of 23.55 
years at lifetime Differences in chemotherapy costs, worse prognosis rates and a 
higher cost of the genomic profile (3,200€ vs. 2,675€ ) explained higher cumulative 
costs for OncotypeDX over both alternatives at any time. MammaPrint instead of 
OncotypeDX showed savings of at least 1,273€ after 5 years. MammaPrint resulted 
dominant (less costly and more effective) against OncotypeDx at any time hori-
zon and would be cost-effective from the 6th year versus A!O (43,912€ , 6,169€ and 
287€ per QALY gained at 5, 10 years and lifetime; 30,000€ /QALY gained thresh-
old assumed). Sensitivity analysis confirmed base case results with MammaPrint 
remaining cost-effective until a willingness-to-pay threshold below 275€ /QALY 
gained. Utility of recurrence, age at baseline and probability of A!O low risk were 
the key drivers at 10 years. ConClusions: MammaPrint in predicting risk of recur-
rence in these patients and avoiding chemotherapy overtreatment is a dominant 
strategy over OncotypeDX and it is highly cost-effective against A!O.
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objeCtives: The clinical utility of biomarkers is often uncertain and difficult to 
demonstrate in an experimental setting. Modeling techniques can be used at the 
preclinical phase to evaluate their potential therapeutic and economic value. In 
multiple myeloma (MM), subgroup analyses of pivotal trials show that only patients 
presenting with adverse prognostic biomarkers demonstrate significantly improved 
survival with bortezomib-based versus some alternative therapies. A cost-utility 
analysis was conducted to evaluate the potential value of a risk-stratified treat-
ment (RST) approach versus uniform treatment (UT) in Dutch daily practice 
MM. Methods: A Markov-type decision analytic model compared total health 
benefits and costs for two strategies: 1) UT where all patients received the standard 
of care consisting of bortezomib induction/maintenance and 2) RST where treat-
ment was stratified according to clinical and tumor biomarkers only, molecular 
biomarkers only, or any biomarker. In RST, high-risk patients received bortezomib 
while other patients received chemotherapy and thalidomide. Input data origi-
nated from clinical trials, literature reviews, observational studies and national 
tariffs. Various sensitivity and scenario analyses were performed. Results: RST 
dominated UT, with average health gains of 0.007-0.059 LYs (0.009-0.040 QALYs) and 
cost-savings of € 1,842-€ 4,924 depending on detection method. A scenario analysis 
for RST where all high-risk patients received an experimental treatment increased 
health by 0.40 LYs (0.30 QALYs) and costs by € 2,567 compared to UT. Influential 
parameters included the price of bortezomib and survival and quality-of-life-related 
parameters. ConClusions: An economic evaluation of biomarkers in the pre-
clinical development phase provided evidence that RST in MM may improve health 
outcomes and lower costs. Modeling techniques made it feasible to assess the cir-
cumstances under which RST would be promising and hence guide the prioritization 
of designing experimental studies to evaluate clinical utility. These findings should 
encourage payers and users to support the clinical development and adoption of 
RST approaches in MM.
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objeCtives: There is an on-going debate about whether to perform surgery on 
early, localized prostate cancer and put up with common long term side effects 
of prostatectomy like incontinence and erectile dysfunction. Alternatively such 
patients could be closely monitored and counselled (active surveillance). This study 
investigates the cost-utility of active surveillance compared to radical prostatec-
tomy. Methods: A Markov model comparing prostatectomy and active surveil-
lance over a lifetime horizon was programmed in TreeAge. Comparative disease 
specific mortality was based on the Scandinavian Prostate Cancer Group trial and 
a review and meta-analysis of comparative effectiveness studies. Resource use 
was identified via national treatment guidelines and expert interviews covering 
in-patient, out-patient, medication, aids & remedies as well as out of pocket pay-
ments. Utility values were literature-based and used as factor weights to age specific 
German HRQoL values. Uncertainty is assessed deterministically and probabilisti-
cally. Results: Our results suggest that active surveillance is a cost saving treat-
ment strategy generating more QALYs at reduced overall costs. The probability of 
developing metastases under AS and the probability of recurrence as well as utility 
weights of patients under AS and after prostatectomy were major drivers of cost-
effectiveness. Monte Carlo simulation suggests that PE is likely to become at willing-
ness to pay thresholds > €400,000. ConClusions: Active surveillance is likely to 
be a cost effective treatment option from the perspective of the German Statuary 
Health Insurance. An improved way of identifying cancers with a high probability 
of progression could favour active surveillance more clearly. It is not clear yet how 
the use of individual utilities for side effects would alter the results.
